跳转至内容
Merck
CN

481480

NF-κB SN50

≥97% (HPLC), lyophilized, NF-κB translocation inhibitor, Calbiochem®

别名:

NF-κB SN50，细胞渗透性抑制剂肽

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C129H230N36O29S
分子量:
2781.50
UNSPSC Code:
12352200
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

NF-κB SN50，细胞渗透性抑制剂肽, NF-κB SN50, CAS 213546-43-3, is a cell-permeable peptide that contains the NLS sequence of NF-κB p50 linked to the hydrophobic region of K-FGF. Inhibits translocation of the NF-κB into the nucleus.

assay

≥97% (HPLC)

form

lyophilized

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
desiccated (hygroscopic)

solubility

water: 5 mg/mL

shipped in

ambient

storage temp.

−20°C

Quality Level

100

相关类别

Biochem/physiol Actions

主要靶标
NF-κB活性复合物进入细胞核的易位
产物不与ATP竞争。
细胞可渗透性：具有

Disclaimer

毒性：标准处理（A）

General description

NF-κB SN50，CAS 213546-43-3，是一种细胞可渗透的肽，其包含与K-FGF疏水区连接的NF-κB p50的NLS序列。抑制NF-κB易位进入细胞核。
包含与Kaposi成纤维细胞生长因子（K-FGF）信号肽的疏水区（h-区）相连的转录因子NF-κB p50的核定位序列（NLS）。N端K-FGF h区赋予细胞通透性，而NLS（360-369）抑制NF-κB活性复合物易位进入细胞核。在LPS诱导的小鼠内皮LE-II细胞中，NF-κB核易位在18 µM时受到最大抑制。

Legal Information

根据美国专利号5,807,746和6,043,339的许可证销售，仅供研究使用。 可通过联系Vanderbilt University（Nashville，Tennessee）获得商业生产、商业用途、诊断或治疗许可证。
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

H-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro-OH
Lin, Y.-Z., et al. 1995.J. Biol. Chem. 270, 14255.

Physical form

作为三氟乙酸盐提供。

Preparation Note

复溶后，等分并冷冻保存（-20°C）。贮备液在-20°C下可稳定保存至多3个月。避免溶液反复冻融。

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Johanna R Reed et al.
PloS one, 7(9), e45877-e45877 (2012-10-03)
Tumor formation is an extensive process requiring complex interactions that involve both tumor cell-intrinsic pathways and soluble mediators within the microenvironment. Tumor cells exploit the intrinsic functions of many soluble molecules, including chemokines and their receptors, to regulate pro-tumorigenic phenotypes
Taewoo Yang et al.
Journal of experimental & clinical cancer research : CR, 41(1), 82-82 (2022-03-05)
BCR-ABL-independent drug resistance is a barrier to curative treatment of chronic myeloid leukemia (CML). However, the molecular pathways underlying BCR-ABL-independent tyrosine kinase inhibitor (TKI) resistance remain unclear. In silico bioinformatic analysis was performed to identify the most active transcription factor

相关内容

PRODUCTO REGULADO POR LA SAGARPA
Pathways and Biomarkers of Toll-like Receptor (TLR) Signaling

"Toll-like Receptors (TLRs) are transmembrane proteins that are expressed on various immune cells. The extracellular N-terminal region of TLRs recognizes specific pathogen components. At least 13 different members of TLR family have been identified that detect different pathogen associated molecular patterns (PAMPs), including lipopolysaccharides, flagellin, bacterial CpG DNA, and viral RNA and DNA. Recognition of PAMPs by TLRs is considered as a key process for the induction of an inflammatory response."

PRODUCTO REGULADO POR LA SECRETARÍA DE SALUD

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持